Vmbook Online ordering

Biotechnology

Recro Pharma, Inc. (REPH) is a specialty pharmaceutical company focused on developing and commercializing therapeutics for the hospital and other acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor.

In terms of financials, Recro Pharma reported a net loss of $15.5 million for the full year 2020, compared to a net loss of $23.4 million in 2019. The company's revenue for 2020 was $11.1 million, compared to $0.4 million in 2019. The increase in revenue was primarily due to the recognition of deferred revenue related to the sale of the company's manufacturing facility in Gainesville, Georgia.

As of December 31, 2020, Recro Pharma had cash and cash equivalents of $23.3 million, compared to $32.1 million as of December 31, 2019.

Regarding growth, Recro Pharma's lead product candidate, intravenous (IV) meloxicam, has the potential to address unmet medical needs in the hospital and other acute care settings. The company has completed a Phase III clinical trial for IV meloxicam in patients undergoing total knee arthroplasty and is planning to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2021.

However, it is important to note that investing in stocks always carries risk, and one should conduct their own research or consult with a financial advisor before making investment decisions. Also, the information provided here is based on publicly available data as of the date of this answer and may change over time.